Semaglutide in the treatment of obesity and overweight

Authors

DOI:

https://doi.org/10.33448/rsd-v12i3.40656

Keywords:

GLP-1 agonists; Semaglutide; Obesity; Medicine.

Abstract

Introduction: The increasing prevalence of obesity in recent decades has become a major health problem worldwide. Semaglutide 2.4 mg once weekly was approved by the FDA in June 2021 for the treatment of overweight/obese individuals. The purpose of this study is to investigate the efficacy and safety of semaglutide in the treatment of obesity in patients who do not have diabetes mellitus. Methodology: This is an integrative literature review that qualitatively addresses the efficacy of semaglutide in the treatment of obesity and overweight. The guiding question was: "Is semaglutide effective in the treatment of obesity and overweight? The search occurred in the main databases, using the descriptors "semaglutide", "obesity", and "overweight". After applying all inclusion and exclusion criteria, a sample of 6 studies was obtained. Results and discussion: The articles exposed in this study served to consolidate the safety and efficacy of the use of subcutaneous semaglutide at a dose of 2.4 mg in non-diabetic patients in order to promote weight loss and reduce cardiometabolic risk. This medication has been shown to be superior to placebo and to another GLP-1 agonist, liraglutide. The main adverse effects are gastrointestinal reactions such as nausea and diarrhea, which tend to decrease over time, as observed in clinical trials. Conclusion: The use of semaglutide has proven safe at the dose of 2.4 mg recommended by the FDA and consolidated by several clinical trials conducted in recent years.

Author Biographies

Izadora Pires de Oliveira, Universidade José do Rosário Vellano

Izadora Pires de Oliveira, acadêmica de Medicina na Universidade José do Rosário Vellano - UNIFENAS

Fernando Garcia Lino, Faculdade de Medicina Claretiano

Fernando Garcia Lino, acadêmico de Medicina na Faculdade de Medicina Claretiano, em Rio Claro

Jéssica Laís Rossin Rabano, Universidade José do Rosário Vellano

Jéssica Laís Rossin Rabano, acadêmica de Medicina na Universidade José do Rosário Vellano - UNIFENAS

Juliana Reis Silva, Universidade José do Rosário Vellano

Juliana Reis Silva, acadêmica de Medicina na Universidade José do Rosário Vellano - UNIFENAS

Ligia Zapata de Oliveira, Universidade José do Rosário Vellano

Ligia Zapata de Oliveira, acadêmica de Medicina da Universidade José do Rosário Vellano - UNIFENAS

Poliana Pezzotto, Universidade José do Rosário Vellano

Poliana Pezzotto, acadêmica de Medicina na Universidade José do Rosário Vellano - UNIFENAS

Tiago Luis Machado Miranda, Universidade José do Rosário Vellano

Tiago Luis Machado Miranda, acadêmico de Medicina na Universidade José do Rosário Vellano - UNIFENAS

Verônica Galvão Brunhara, Universidade José do Rosário Vellano

Verônica Galvão Brunhara, acadêmica de Medicina na Universidade José do Rosário Vellano - UNIFENAS

Éric Àzara de Oliveira, Universidade José do Rosário Vellano

Éric Àzara de Oliveira, acadêmico de Medicina na Universidade José do Rosário Vellano - UNIFENAS

References

Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017). Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, obesity & metabolism, 19(9), 1242–1251. https://doi.org/10.1111/dom.12932

Chao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2021). Semaglutide for the treatment of obesity. Trends in cardiovascular medicine, S1050-1738(21)00158-4. Advance online publication. https://doi.org/10.1016/j.tcm.2021.12.008

Deng, Y., Park, A., Zhu, L., Xie, W., & Pan, C. Q. (2022). Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review. Therapeutic Advances in Chronic Disease, 13, 20406223221108064.

Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell metabolism, 27(4), 740-756.

Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10). https://doi.org/10.1038/S41591-022-02026-4

Hermont, A. P., Zina, L. G., da Silva, K. D., da Silva, J. M., & Martins-Júnior, P. A. (2021). Revisões integrativas em Odontologia: conceitos, planejamento e execução.Arquivos em Odontologia,57, 3-7.

Knudsen, L. B., & Lau, J. (2019). The Discovery and Development of Liraglutide and Semaglutide. Frontiers in endocrinology, 10, 155. https://doi.org/10.3389/fendo.2019.00155

Mendes, K. D. S. et al. (2008). Revisão integrativa: Método de Pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & contexto-enfermagem, 17(4), 758-64.

Peters, U.; Dixon, A. E.; & Forno, E. (2018) Obesity and asthma. Journal of Allergy and Clinical immunology, 141(4), 1169-1179, 2018.

Phillips, A., & Clements, J. N. (2022). Clinical review of subcutaneous semaglutide for obesity. Journal of clinical pharmacy and therapeutics, 47(2), 184–193. https://doi.org/10.1111/jcpt.13574

Purdy, J. C., & Shatzel, J. J. (2021). The hematologic consequences of obesity. European Journal of Haematology, 106(3), 306-319.

Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., & Garvey, W. T. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA, 327(2), 138–150. https://doi.org/10.1001/JAMA.2021.23619

Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., & Dicker, D. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/JAMA.2021.3224

Silva, C. C. et al. (2020). Acesso e utilização de serviços odontológicos por gestantes: revisão integrativa de literatura. Ciência & Saúde Coletiva25,827-835

Simonson, M., Boirie, Y., & Guillet, C. (2020). Protein, amino acids and obesity treatment. Reviews in Endocrine and Metabolic Disorders, 21(3), 341-353.

Sousa, L. M.M., Marques-Vieira, C. M. A., Severino, S. S., & Antunes, A. V. (2017). A metodologia de revisão integrativa da literatura em enfermagem.Rev. Inv. Enferm., 2(21) 17–26. https://repositorio-cientifico.essatla.pt/bitstream/20.500.12253/1311/1/Metodologia%20de%20Revis%c3%a3o%20Integrativa_RIE21_17-26

Souza, M. T. de; Silva, M. D. da; & Carvalho, R. de. (2010) Revisão integrativa: o que é e como fazer. Einstein (São Paulo), 8, 102-106, 2010.

Stadler, J. T., & Marsche, G. (2020). Obesity-related changes in high-density lipoprotein metabolism and function. International Journal of Molecular Sciences, 21(23), 8985.

Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., Wallenstein, S. O. R., & Garvey, W. T. (2021). Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA, 325(14), 1403–1413. https://doi.org/10.1001/JAMA.2021.1831

Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., Kelly, A. S., Mastrandrea, L. D., Sørrig, R., & Arslanian, S. (2022). Once-Weekly Semaglutide in Adolescents with Obesity. The New England Journal of Medicine, 387(24). https://doi.org/10.1056/NEJMOA2208601

Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMOA2032183

Published

20/03/2023

How to Cite

OLIVEIRA, I. P. de .; LINO, F. G. .; RABANO, J. L. R. .; SILVA, J. R. .; OLIVEIRA, L. Z. de .; PEZZOTTO, P.; MIRANDA, T. L. M. .; BRUNHARA, V. G. .; OLIVEIRA, Éric Àzara de .; ROCHA, C. M. . Semaglutide in the treatment of obesity and overweight. Research, Society and Development, [S. l.], v. 12, n. 3, p. e29812340656, 2023. DOI: 10.33448/rsd-v12i3.40656. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/40656. Acesso em: 10 oct. 2024.

Issue

Section

Review Article